Corbus Pharmaceuticals (CRBP) announced the appointment of Dr. Dominic Smethurst, MA MRCP, as the Company’s Chief Medical Officer, CMO. In this role, Dr. Smethurst will lead the clinical development of the Company’s investigational oncology drugs: CRB-701, a next generation Nectin-4 targeting antibody drug conjugate developed in partnership with CSPC, and CRB-601, a TGFbeta blocking monoclonal antibody targeting the integrin alphavbeta8. Additionally, Dr. Smethurst will help guide strategic development of CRB-913, the Company’s highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Smethurst most recently served as CMO of Bicycle Therapeutics (BCYC)
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CRBP:
- Corbus Pharmaceuticals Announces Chief Scientific Officer Resignation
- Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Corbus Pharmaceuticals Shares Updated Corporate Insights
- Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Corbus Pharmaceuticals Announces Offering and Pricing Details
